TAVAREC

• Research type

  Research Study

• Full title

  Randomized trial assessing the significance of Bevacizumab in recurrent grade II and Grade III gliomas. The TAVAREC trial.

• IRAS ID

  61943

• Contact name

  Sara Erridge

• Sponsor organisation

  European Organisation for Research and Treatment of Cancer

• Eudract number

  2009-017422-39

• Research summary

  Though low grade gliomas have a reasonable prognosis (years) when they recur, especially if they enhance with IV contrast (a sign of aggressive tumour behaviour), the outlook is poor with a median survival of less than 12 months. It is therefore important to find better treatments for this group of patients. The standard treatment is palliative chemotherapy, with temozolomide the most commonly used agent. Bevacizumab is an agent which affects the blood supply to tumours. Tumours which enhance with IV contrast have new blood vessels which are a potential target for bevacizumab. Bevacizumab is licenced for use in a number of tumour sites e.g. colorectal and lung cancer. It has also been used in high grade glioma but there is no randomised evidence. This international EU study's aim is to see if the addition of bevacizumab to standard treatment can improve the survival of patients with recurrent low grade glioma.

• REC name

  Scotland A REC

• REC reference

  11/MRE00/1

• Date of REC Opinion

  16 Mar 2011

• REC opinion

  Further Information Favourable Opinion